Literature DB >> 17699316

Pro- and anti-inflammatory cytokines in chronic pediatric dialysis patients: effect of aspirin.

Stuart L Goldstein1, Jocelyn C Leung, Douglas M Silverstein.   

Abstract

Dialysis provides effective and safe treatment of ESRD in children, but patients who are maintained on chronic dialysis are at risk for cardiovascular disease. One major risk factor for cardiovascular disease in adult patients with ESRD is chronic inflammation. The effect of anti-inflammatory therapy with aspirin on serum cytokine concentration was studied in seven children who were receiving hemodialysis (HD) and seven who were receiving continuous cycling peritoneal dialysis (CCPD or PD). Dialysis vintage was 4.3 +/- 4.6 yr; single-pool Kt/V was 1.46 +/- 1.4, mean equilibrated Kt/V was 1.27 +/- 0.16, and PD weekly Kt/V was 2.45 +/- 0.30. Baseline proinflammatory cytokine IL-1beta, IL-6, IL-8, and TNF-alpha serum concentrations were significantly elevated, whereas serum anti-inflammatory cytokine IL-4 and IL-10 concentrations were normal. The patterns of cytokine elevation were similar for patients who were receiving HD versus PD. IL-4 and IL-6 concentrations demonstrated strong positive correlation with dialysis vintage (IL-4, P < 0.03; IL-6, P < 0.0001). Pre-aspirin serum cytokine concentrations did not vary with single-pool Kt/V or equilibrated Kt/V for HD patients or with weekly Kt/V for PD patients. Serum IL-8 and TNF-alpha concentrations were significantly reduced by aspirin treatment at 4 mo (P = 0.04 and P = 0.007, respectively). Serum IL-6 concentration decreased with aspirin treatment but not significantly (P = 0.1). Serum IL-1beta concentration remained unchanged, and IL-4 and IL-10 concentrations remained stable throughout aspirin treatment. The effect of aspirin treatment on serum cytokine concentrations was similar for HD and PD patients. In HD patients, IL-6, IL-8, and TNF-alpha remained suppressed 1 mo after discontinuation of aspirin. It is concluded that proinflammatory cytokines are elevated in pediatric HD and PD patients without counterbalance from anti-inflammatory cytokines, and aspirin therapy attenuates inflammation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17699316     DOI: 10.2215/CJN.02291205

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  26 in total

1.  Aspirin reduces lipopolysaccharide-induced pulmonary inflammation in human models of ARDS.

Authors:  U Hamid; A Krasnodembskaya; M Fitzgerald; M Shyamsundar; A Kissenpfennig; C Scott; E Lefrancais; M R Looney; R Verghis; J Scott; A J Simpson; J McNamee; D F McAuley; C M O'Kane
Journal:  Thorax       Date:  2017-01-12       Impact factor: 9.139

2.  Factors Associated with Multiple Biomarkers of Systemic Inflammation.

Authors:  Sandi L Navarro; Elizabeth D Kantor; Xiaoling Song; Ginger L Milne; Johanna W Lampe; Mario Kratz; Emily White
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-01-11       Impact factor: 4.254

3.  Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention Trial.

Authors:  Lauren M Hurwitz; Ibrahim Kulac; Berrak Gumuskaya; Javier A Baena Del Valle; Ines Benedetti; Fan Pan; Jun O Liu; Michael T Marrone; Kathryn B Arnold; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Ian M Thompson; Charles G Drake; William B Isaacs; William G Nelson; Angelo M De Marzo; Elizabeth A Platz
Journal:  Cancer Prev Res (Phila)       Date:  2020-06-24

4.  Frequent hemodialysis with NxStage system in pediatric patients receiving maintenance hemodialysis.

Authors:  Stuart L Goldstein; Douglas M Silverstein; Jocelyn C Leung; Daniel I Feig; Beth Soletsky; Cathy Knight; Bradley A Warady
Journal:  Pediatr Nephrol       Date:  2007-11-08       Impact factor: 3.714

5.  Skeletal muscle growth in young rats is inhibited by chronic exposure to IL-6 but preserved by concurrent voluntary endurance exercise.

Authors:  P W Bodell; E Kodesh; F Haddad; F P Zaldivar; D M Cooper; G R Adams
Journal:  J Appl Physiol (1985)       Date:  2008-12-04

Review 6.  Current advances in chronic kidney disease in children: growth, cardiovascular, and neurocognitive risk factors.

Authors:  Larry A Greenbaum; Bradley A Warady; Susan L Furth
Journal:  Semin Nephrol       Date:  2009-07       Impact factor: 5.299

Review 7.  Cardiovascular disease in CKD in children: update on risk factors, risk assessment, and management.

Authors:  Amy C Wilson; Mark M Mitsnefes
Journal:  Am J Kidney Dis       Date:  2009-08       Impact factor: 8.860

Review 8.  Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease.

Authors:  Douglas M Silverstein
Journal:  Pediatr Nephrol       Date:  2008-12-13       Impact factor: 3.714

9.  Dysregulated chemokine receptor expression and chemokine-mediated cell trafficking in pediatric patients with ESRD.

Authors:  Barbara Sherry; Wei Wei Dai; Martin L Lesser; Howard Trachtman
Journal:  Clin J Am Soc Nephrol       Date:  2008-01-30       Impact factor: 8.237

10.  Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial.

Authors:  Taimur Dad; Hocine Tighiouart; Alin Joseph; Andrew Bostom; Myra Carpenter; Lawrence Hunsicker; John W Kusek; Marc Pfeffer; Andrew S Levey; Daniel E Weiner
Journal:  Am J Kidney Dis       Date:  2016-03-02       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.